Andrew Drechsler, a financial executive with over 25 years of experience in the life science industry, has been named to the Manasquan Bank Board of Directors, effective April 24.
“Andy’s exceptional financial acumen and experience in leading successful life science companies will undoubtedly bring invaluable insights and expertise to our board,” said James Vaccaro, chair, CEO and president of Manasquan Bank.
“His commitment to the bank’s market area only serves to enhance this strategic addition to the board. We are thrilled to have him and look forward to working together to continue driving growth and success for the bank,” Vaccaro said.
Drechsler currently serves as a consultant to development-stage pharmaceutical and biotech companies that are in their startup phase. Previously, he was the CFO of Provention Bio, which was later acquired by Sanofi in 2023.
He has also served as the CFO of Insmed Incorporated, VaxInnate Corporation and Valera Pharmaceuticals, where he played a large role in securing financial transactions and overseeing operations.
“I’m honored to join Manasquan Bank’s Board of Directors and be a part of an organization that values community involvement as much as I do,” Drechsler said. “As a lifelong Monmouth County resident, I’ve always admired the bank’s commitment to serving its local community, and I look forward to contributing my experience and expertise to help continue building on Manasquan Bank’s 150-year legacy of stability and service excellence.”
Drechsler holds a bachelor’s degree in accounting, graduating magna cum Laude from Villanova University. He is also a board member of the NJ Chapter of the Juvenile Diabetes Research Foundation (JDRF).
